Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity markets widen losses
Mon, 7 Oct 01:30 pm

Indian markets slipped deeper into the red during the post noon trading session. Barring stocks from Healthcare, IT and Metal sectors all the sectoral indices are trading in negative territory. Banking stocks are witnessing maximum selling pressure.

BSE-Sensex is down by 114 points and NSE-Nifty is trading down by 33 points. However, BSE Mid Cap is trading up by 0.22% while the BSE Small Cap Cap index is trading up by 0.31%.The rupee is trading at 61.86 to the US dollar.

Most of the Indian pharma stocks are trading in green with Dishman pharma and Wockhardt Ltd leading the pack of gainers. As per the financial daily, Ranbaxy laboratories is looking to buy a facility in India to manufacture the drugs for the US market. Reportedly, the company is looking for several options to shift its blockbuster drugs which are pending approval in the US market. The acquired facility will help the company to reduce its risk arising out of the issues in its three of the four US approved facilities. Further, this step comes after the company had received import alert to its Mohali unit in India. Currently, all the three manufacturing plants located in India are undergoing USFDA surveillance, and hence the company's only operational facility is Ohm laboratories located in US. Buying new facility in India will help in cost arbitrage. Ranbaxy was trading up by 2.1% at the time of writing.

Majority of the public sector banks are trading in the red with Bank of Maharashtra and Bank of Baroda being the biggest losers. Indian Bank and Dena Bank are among the few stocks trading in the green. As per a leading financial daily, State Bank of India is the largest bank in the country but lags behind in critical parameters such as business and profit generation capacity according to a report released by Reserve bank of India (RBI). The report titled 'A Profile of Banks: 2012-13' released by RBI states that in FY13, the business per employee of SBI stood at Rs 94.3 m while the overall average for banks was Rs 121.3 m. The average profit contribution by an SBI employee was Rs 6.5 lakh as compared to banking aggregate of Rs 8.3 lakh. Even the net non performing assets (NPA) of the bank at 2.1% of total advances were higher than the bank aggregate value of 1.7%in FY13. However the bank has scored on the profitability front, reporting a net interest margin (NIM) of 3.06% as compared to bank aggregate value of 2.79% during the year. SBI's stock is currently trading down by 1.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets widen losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.